C12N 2730/10011
Hepadnaviridae
C12N2730/10011 (Hepadnaviridae) appears on 1,054 US grants and 1,264 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,054
- Published applications
- 1,264
- Assignees
- 698
- Inventors
- 2,529
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 2 | 0 |
| 1978 | 8 | 0 |
| 1979 | 5 | 0 |
| 1980 | 7 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 3 | 0 |
| 1984 | 4 | 0 |
| 1985 | 9 | 0 |
| 1986 | 10 | 0 |
| 1987 | 15 | 0 |
| 1988 | 11 | 0 |
| 1989 | 20 | 0 |
| 1990 | 13 | 0 |
| 1991 | 15 | 0 |
| 1992 | 21 | 0 |
| 1993 | 11 | 0 |
| 1994 | 8 | 0 |
| 1995 | 9 | 0 |
| 1996 | 18 | 0 |
| 1997 | 24 | 0 |
| 1998 | 46 | 0 |
| 1999 | 30 | 0 |
| 2000 | 46 | 0 |
| 2001 | 31 | 9 |
| 2002 | 31 | 40 |
| 2003 | 30 | 88 |
| 2004 | 17 | 70 |
| 2005 | 18 | 60 |
| 2006 | 33 | 59 |
| 2007 | 20 | 45 |
| 2008 | 30 | 49 |
| 2009 | 25 | 54 |
| 2010 | 24 | 63 |
| 2011 | 33 | 57 |
| 2012 | 25 | 46 |
| 2013 | 24 | 40 |
| 2014 | 43 | 56 |
| 2015 | 18 | 48 |
| 2016 | 40 | 63 |
| 2017 | 25 | 57 |
| 2018 | 40 | 32 |
| 2019 | 35 | 47 |
| 2020 | 32 | 44 |
| 2021 | 29 | 45 |
| 2022 | 28 | 60 |
| 2023 | 22 | 39 |
| 2024 | 23 | 40 |
| 2025 | 29 | 30 |
| 2026 | 8 | 23 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2730/10111OrthohepadnavirusIndexing code1,048
- C12N 2730/10023Virus like particles [vlp]Indexing code8
- C12N 2730/10034Use of virus or viral component as vaccineIndexing code8
- C12N 2730/10022New viral proteins or individual genes, new structural or functional aspects ofIndexing code3
- C12N 2730/10041Use of virus, viral particle or viral elements as a vectorIndexing code3
- C12N 2730/10051Methods of production or purification of viral materialIndexing code2
- C12N 2730/10071Demonstrated in vivo effectIndexing code1
- C12N 2730/10021Viruses as suchIndexing code0
All 13 subgroupsShow fewer
- C12N 2730/10031Uses of virus other than therapeutic or vaccineIndexing code0
- C12N 2730/10032Use of virus as therapeutic agent, other than vaccineIndexing code0
- C12N 2730/10033Use of viral protein as therapeutic agent other than vaccineIndexing code0
- C12N 2730/10061Methods of inactivation or attenuationIndexing code0
- C12N 2730/10088For redistributionIndexing code0
Recent patents
- Treatment of diseases related to hepatitis B virus18 Aug 2026US 12,709,634 B2Erasmus University Medical Center Rotterdam
- Hepadnavirus capsid protein heterodimers and virus-like particles28 Apr 2026US 12,612,433 B2The Trustees of Indiana University
- Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same21 Apr 2026US 12,605,444 B2The Wistar Institute
- Hepatitis B virus-specific T cell responses14 Apr 2026US 12,599,658 B2Oregon Health & Science University
- Compositions and methods for long term culture of hepatocytes24 Mar 2026US 12,584,111 B2Peking University
- Tumor neoantigen vaccine system specifically marking heterologous protein, and use thereof8 Oct 2026US 2026/0306620 A1China Pharmaceutical University
- Virus-like structured nano-connector and method thereof17 Sep 2026US 2026/0273077 A1Eye Hospital of Shandong First Medical University (Shandong Eye Hospital
- Oligonucleotides for use in modulating immune responses against hepatitis b viral infection3 Sep 2026US 2026/0256907 A1Ausperbio Therapeutics Inc.
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
- Compositions and methods for treating viral infections6 Aug 2026US 2026/0226474 A1The University of Sydney
Most cited
By later US patents
- Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity737US 4,554,101 ANew York Blood Center, Inc. · 1985
- Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and compositions thereof519US 5,723,323 A1998
- Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant395US 6,406,705 B1Coley Pharmaceutical GmbH · 2002
- Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix365US 6,309,669 B1The United States of America as represented by the Secretary of the Army · 2001
- Process for the production of stochastically-generated transcription or translation products347US 5,814,476 A1998